| Drug |
Interaction |
| Abacavir |
Tipranavir decreases the concentration of Abacavir. |
| Alprazolam |
Tipranavir may decrease the metabolism and clearance of Alprazolam. Consider alternate therapy or monitor for Alprazolam toxic effects if Tipranavir is initiated or dose increased. |
| Amiodarone |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Amiodarone. Concomitant therapy is contraindicated. |
| Amlodipine |
Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Amlopidine. Monitor for changes in Amlopidine therapeutic and toxic effects if Tipranavir is initiated, discontinued or dose changed. |
| Astemizole |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Astemizole. Concomitant therapy is contraindicated. |
| Atazanavir |
Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Atazanavir. Consider alternate therapy. |
| Atorvastatin |
Tipranavir, co-administered with Ritonavir, increases the adverse/toxic effects of Atorvastatin. Concomitant therapy should be avoided. |
| Bepridil |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Bepridil. Concomitant therapy is contraindicated. |
| Bromazepam |
Tipranavir may decrease the metabolism and clearance of Bromazepam. Consider alternate therapy or monitor for Bromazepam toxic effects if Tipranavir is initiated or dose increased. |
| Bromocriptine |
Tipranavir may increase the plasma concentration of Bromocriptine. Concomitant therapy should be avoided. |
| Budesonide |
Tipranavir may increase the plasma concentration of Budesonide. Monitor for toxic Budesonide effects during concomitant administration. |
| Carbamazepine |
Concomitant use may result in decreased Tipranavir and increased Carbamazepine concentrations. |
| Chlordiazepoxide |
Tipranavir may decrease the metabolism and clearance of Chlordiazepoxide. Consider alternate therapy or monitor for Alprazolam toxic effects if Tipranavir is initiated or dose increased. |
| Cisapride |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Cisapride. Concomitant therapy is contraindicated. |
| Clarithromycin |
The concentrations of Tipranavir and Clarithromycin increase during concomitant therapy. Dose adjustments are required for patients with renal impairment. |
| Clobazam |
Tipranavir may decrease the metabolism and clearance of Clobazam. Consider alternate therapy or monitor for Clobazam toxic effects if Tipranavir is initiated or dose increased. |
| Clonazepam |
Tipranavir may decrease the metabolism and clearance of Clonazepam. Consider alternate therapy or monitor for Clonazepam toxic effects if Tipranavir is initiated or dose increased. |
| Clorazepate |
Tipranavir may decrease the metabolism and clearance of Clorazepate. Consider alternate therapy or monitor for Clorazepate toxic effects if Tipranavir is initiated or dose increased. |
| Conjugated Estrogens |
Conjugated estrogens may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Conjugated estrogens. Monitor for estrogen deficiency during concomitant therapy. |
| Cyclosporine |
Tipranavir may affect the efficacy/toxicity of Cyclosporine. |
| Delavirdine |
Concomitant use may result in increased Tipranavir and decreased Delavirdine concentrations. Monitor for altered therapeutic and adverse effects of both agents if either agent is initiated, discontinued or dose changed. |
| Desipramine |
Tipranavir, co-administered with Ritonavir, may increase the concentration of Desipramine. Monitor Desipramine concentration and efficacy/toxicity and adjust dose as required. |
| Diazepam |
Tipranavir may decrease the metabolism and clearance of Diazepam. Consider alternate therapy or monitor for Diazepam toxic effects if Tipranavir is initiated or dose increased. |
| Didanosine |
Tipranavir decreases the concentration of Didanosine. |
| Diethylstilbestrol |
Diethylstilbestrol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Diethylstilbestrol. Monitor estrogen levels during concomitant therapy. |
| Dihydroergotamine |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Dihydroergotamine. Concomitant therapy is contraindicated. |
| Diltiazem |
Tipranavir, co-administered with Ritonavir, may alter the concentration of Diltiazem. Monitor for efficacy and adverse/toxic effects of Diltiazem. |
| Disulfiram |
Disulfiram may cause Tipranavir (Aptivus brand) toxicity by inhibiting alcohol metabolism. Aptivus capsules contain alcohol. |
| Efavirenz |
Efavirenz may alter the serum concentration Tipranavir. Monitor for changes in Tipranavir therapeutic and adverse effects if Efavirenz is initiated, discontinued or dose changed. |
| Ergoloid mesylate |
Tipranavir may increase the plasma concentration of Ergoloid mesylates. Concomitant therapy should be avoided. |
| Ergonovine |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Ergonovine. Concomitant therapy is contraindicated. |
| Ergotamine |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Ergotamine. Concomitant therapy is contraindicated. |
| Esomeprazole |
Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Esomeprazole. Consider alternate therapy or increase the dose of Esomeprazole based on the therapeutic response. |
| Estazolam |
Tipranavir may decrease the metabolism and clearance of Estazolam. Consider alternate therapy or monitor for Estazolam toxic effects if Tipranavir is initiated or dose increased. |
| Estradiol |
Estradiol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Estradiol. Use an alternate form of contraception or monitor for estrogen deficiency if Estradiol is used for hormone replacement therapy. |
| Estrone |
Estropipate may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Estropipate. Monitor for estrogen deficiency during concomitant therapy. |
| Ethinyl Estradiol |
Tipranavir, co-administered with Ritonavir, decreases Ethinyl estradiol concentrations. Ethinyl estradiol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Use an alternate form of contraception or monitor for estrogen deficiency if Ethinyl estradiol is used for hormone replacement therapy. |
| Etravirine |
Tipranavir, co-administered with Ritonavir, may decrease the effect of Etravirene by decreasing Etravirene serum concentration. Concomitant therapy should be avoided. |
| Felodipine |
Tipranavir, co-administered with Ritonavir, may alter the concentration of Felopidine. Monitor for efficacy and adverse/toxic effects of Felopidine. |
| Flecainide |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Flecainide. Concomitant therapy is contraindicated. |
| Fluconazole |
Fluconazole may increase the serum concentration of Tipranavir. Dose adjustments are not required. |
| Fluoxetine |
Tipranavir increases the concentration of Fluoxetine. The Fluoxetine dose may require an adjustment. |
| Flurazepam |
Tipranavir may decrease the metabolism and clearance of Flurazepam. Consider alternate therapy or monitor for Flurazepam toxic effects if Tipranavir is initiated or dose increased. |
| Fluticasone Propionate |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Fluticasone propionate. Concomitant therapy should be avoided if possible. |
| Fosamprenavir |
Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Fosamprenavir. Consider alternate therapy. |
| Fusidic Acid |
Concomitant therapy of Tipranavir with Fusidic acid may result in increased serum concentrations of both agents. Consider alternate therapy or monitor for increased serum concentrations and toxocity of both agents. |
| Isradipine |
Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Isradipine. Monitor for changes in Isradipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed. |
| Itraconazole |
Tipranavir may increase the serum concentration of Itraconazole. |
| Ketoconazole |
Tipranavir may increase the serum concentration of Ketoconazole. |
| Lopinavir |
Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Lopinavir. Consider alternate therapy. |
| Lovastatin |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Lovastatin. Concomitant therapy is contraindicated. |
| Meperidine |
Tipranavir may increase the adverse/toxic effects of Meperidine. Consider alternate therapy or monitor for Meperidine toxicity during concomitant use. |
| Mestranol |
Mestranol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Mestranol. Use an alternate form of contraception or monitor for estrogen deficiency if Mestranol is used for hormone replacement therapy. |
| Methadone |
Tipranavir, co-administered with Ritonavir, decreases the Methadone concentration. Monitor for symptoms of opiate withdrawal. |
| Methylergonovine |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Methylergonovine. Concomitant therapy is contraindicated. |
| Midazolam |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Midazolam. Concomitant therapy is contraindicated. |
| Nevirapine |
Nevirapine, a CYP3A4 inducer, may decrease the serum concentration of Tipranavir, a CYP3A4 substrate. Monitor for changesin Tipranavir effect if Nevirapine is initiated, discontinued or dose changed. |
| Nicardipine |
Tipranavir, co-administered with Ritonavir, may alter the concentration of Nicardipine. Monitor for efficacy and adverse/toxic effects of Nicardipine. |
| Nifedipine |
Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nifedipine. Monitor for changes in Nifedipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed. |
| Nimodipine |
Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nimodipine. Monitor for changes in Nimodipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed. |
| Nisoldipine |
Tipranavir, co-administered with Ritonavir, may alter the concentration of Nisoldipine. Monitor for efficacy and adverse/toxic effects of Nisoldipine. |
| Nitrendipine |
Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nitrendipine. Monitor for changes in Nitrendipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed. |
| Omeprazole |
Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Omeprazole. Consider alternate therapy or increase the dose of Omeprazole based on the therapeutic response. |
| Paroxetine |
Tipranavir increases the concentration of Paroxetine. The Paroxetine dose may require an adjustment. |
| Pergolide |
Tipranavir may increase the plasma concentration of Pergolide. Concomitant therapy should be avoided. |
| Phenobarbital |
Phenobarbial decreases the concentration of Tipranavir. Monitor for decreased Tipranavir efficacy. |
| Phenytoin |
Phenytoin decreases the concentration of Tipranavir. Monitor for decreased Tipranavir efficacy. |
| Pimozide |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Pimozide. Concomitant therapy is contraindicated. |
| Posaconazole |
Tipranavir may increase the serum concentration of Posaconazole. Posaconazole may increase the serum concentration of Tipranavir. |
| Pravastatin |
Tipranavir may increase the plasma concentration of Pravastatin. Consider alternate therapy. |
| Prazepam |
Tipranavir may decrease the metabolism and clearance of Prazepam. Consider alternate therapy or monitor for Prazepam toxic effects if Tipranavir is initiated or dose increased. |
| Propafenone |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Propafenone. Concomitant therapy is contraindicated. |
| Quazepam |
Tipranavir may decrease the metabolism and clearance of Quazepam. Consider alternate therapy or monitor for Quazepam toxic effects if Tipranavir is initiated or dose increased. |
| Quinidine |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Quinidine. Concomitant therapy is contraindicated. |
| Rifabutin |
Tipranavir increases the concentration of Rifabutin. Adjust Rifabutin dose and monitor for adverse/toxic effects. |
| Rifampin |
Rifampin may decrease the plasma concentration of Tipranavir. Concomitant use is not recommended. |
| Rifapentine |
Concomitant therapy may cause decreased Tipranavir and increased Rifapentine plasma concentrations. |
| Rosuvastatin |
Concomitant therapy of Rosuvastatin and Tipranavir/Ritonavir may increase Rosuvastatin and Tipranavir concentrations. Consider alternate therapy. |
| Saquinavir |
Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Saquinavir. Consider alternate therapy. |
| Sertraline |
Tipranavir increases the concentration of Sertraline. The Sertraline dose may require an adjustment. |
| Sildenafil |
Tipranavir, co-administered with Ritonavir, may increase the concentration of Sildenafil. Alternate therapy should be considered. |
| Simvastatin |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Simvastatin. Concomitant therapy is contraindicated. |
| Sirolimus |
Tipranavir may affect the efficacy/toxicity of Sirolimus. |
| Sodium bicarbonate |
Sodium bicarbonate may decrease the absorption of Tipranavir. Separate administration of the agents and monitor for decreased efficacy of Tipranavir. |
| St. John's Wort |
St. John's Wort may decrease the concentration and efficacy of Tipranavir. Concomitant therapy should be avoided. |
| Tacrolimus |
Tipranavir may decrease the metabolism and clearance of Tacrolimus. Dose adjustments may be required. Monitor for Tacrolimus efficacy and toxicity during concomitant therapy. |
| Tadalafil |
Tipranavir, co-administered with Ritonavir, may increase the concentration of Tadalafil. Alternate therapy should be considered. |
| Temsirolimus |
Tipranavir may affect the efficacy/toxicity of Temsirolimus. |
| Terfenadine |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Terfenadine. Concomitant therapy is contraindicated. |
| Theophylline |
Tipranavir, co-administered with Ritonavir, may decrease the concentration of Theophylline. |
| Trazodone |
Tipranavir increases the concentration of Trazodone. Monitor for adverse/toxic effects of Trazodone. Trazodone dose adjustment may be necessary. |
| Triazolam |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Triazolam. Concomitant therapy is contraindicated. |
| Valproic Acid |
Tipranavir decreases the concentration of Valproic acid. Monitor Valproid acid efficacy. |
| Vardenafil |
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Vardenafil. Concomitant therapy is contraindicated. |
| Verapamil |
Tipranavir, co-administered with Ritonavir, may alter the concentration of Verapamil. Monitor for efficacy and adverse/toxic effects of Verapamil. |
| Voriconazole |
Tipranavir may alter the serum concentration of Voriconazole. |
| Zidovudine |
Tipranavir decreases the concentration of Zidovudine. |